Hematopoetic lineage concept to proove surface marker in flowcytometry

Lini maturasi hematopoetic

1. Presentan : Nur Fii Hidayatullah Pembimbing : Prof. Dr. J.B Suparyatmo , dr , SpPK , Subsp. H.K-K Kode MK : 06107340407 A History and Current Understanding of Acute Erythroid Leukemia Coltoff Alexander Program Pendidikan Dokter Spesialis Patologi Klinik Fakultas Kedokteran Universitas Sebelas Maret Surakarta 2024

2. Figure 11.38.  Erythroid /myeloid leukemia ( erythroleukemia (AML-M6a)). Bone marrow smears show erythroid preponderance and left shift with increased myeloblasts : (a) low power and (b) high power. Morphologic category AML M6a

3. Figure 11.39.  Erythroid /myeloid leukemia ( erythroleukemia , AML-M6a). (a) Bone marrow biopsy section showing hypercellular marrow with increased immature cells. (b) Bone marrow smears show erythroid preponderance and left shift with increased myeloblasts . Inset shows an erythroid precursor with coarse PAS positive cytoplasmic granules. Morphologic category AML M6a

4. Figure 11.40. Pure erythroid leukemia (AML-M6b). Biopsy section reveals a markedly hypercellular marrow with sheets of blasts and immature erythroid cells: (b) high power. Bone marrow smear shows erythroid preponderance with increased erythroblasts (c). Morphologic category AML M6b

5. Molecular Biology and Genomic Features of AEL

6. Molecular Change and the Critical Step of AEL Erythropoietin Receptor (EPOR); Janus Kinase (JAK); Signal Transcription Activators (STATs); extracellular signal-regulated (ERK) kinases ; PhosphoInositide 3 Kinase (PI3K) Mitogen -Activated Protein (MAP) Signal Transcription Activators (STATs) Phospho Inositide 3 Kinase (PI3K)

7. Development Therapies for AEL Erythropoietin Receptor (EPOR); Janus Kinase (JAK); Signal Transcription Activators (STATs); extracellular signal-regulated (ERK) kinases ; PhosphoInositide 3 Kinase (PI3K) Preventing Displacia Epretonopt Azacitidine Inhibits Activity of EPOR, JAK2 Inhibits Metilation by HMA + PARP Inhibits Activation of STAT5 Inhibits DNA Change CDX4/7/9 Induce p53 activity by BCL-2/BCL-XL, COS-9, COTI-2 Antibody Monoclonal Magrolinab

8. Previous clinical studies on Acute Erythroid Leukemia and their respective outcomes

9. Previous clinical studies on Acute Erythroid Leukemia and their respective outcomes